Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system. The aim of this work was to study the probiotic effect of γ-aminobutyric acid (GABA)-producer Lactobacillus brevis BGZLS10-17 on experimental autoimmune encephalomyelitis (EAE), an experimental animal MS model. Clinical EAE symptoms were monitored in Dark Agouti (DA) rats treated with L. brevis BGZLS10-17 strain, or supernatant obtained from 48 h culture of L. brevis BGZLS10-17 cultivated in growth medium with or without GABA precursor monosodium glutamate (MSG). The results revealed that oral administration of L. brevis BGZLS10-17 alleviates the symptoms of EAE in DA rats. Namely, treatment with BGZLS10-17 and the supernatant of the strain cultivated in medium with MSG delayed the onset, shortened the duration, and reduced the intensity of the disease in the period when the EAE symptoms in controls were most pronounced. The probiotic treated animals were completely recovered after forty days, unlike the control animals. The results indicate that supplementation with live strain or with supernatant containing GABA produced by L. brevis BGZLS10-17 could alleviate the EAE symptoms. However, the use of L. brevis BGZLS10-17 in functional food as probiotic for autoimmune diseases should be tested in clinical trials.
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease of central nervous system (CNS) often leading to severe physical or cognitive disability and neurological defects 1 . MS is characterized by multifocal demyelination and axons damage resulting in dysfunction and death of neurons, mostly targeting the young adults 2 . The cause of the disease is still unknown, although it seems to be a combination of genetic susceptibility and non-genetic and environmental factors 3 . MS was recently linked to gut microbiota dysbiosis 4, 5 . The connection between the brain and gastrointestinal tract-GIT (gut brain axis, GBA) is a two-way communication between the central and enteric nervous systems. The link between the GIT microbiota and GBA is also bidirectional and occurs via neural, endocrine, immune, and humoral factors 6 . The balance between the microbiota and the intestinal barrier is disturbed during chronic inflammation and autoimmune diseases, and one of the very attractive fields of research is the use of certain microorganisms to restore the balance.
The etiology of MS is related to reduced level of plasma GABA and activities of enzyme glutamic acid decarboxylase (GAD) 7 . A number of clinical studies investigated glutamate and γ-aminobutyric acid (GABA) levels in MS patients. The lower glutamate levels in sensorimotor and parietal regions of the left cerebral hemisphere of the brain, as well as higher GABA levels in sensorimotor region were detected in MS patients compared to healthy controls 8 . On the other hands, significantly lower GABA and glutamate levels, associated with verbal and visuospatial memory deficits, were reported in relapsing remitting MS patients compared to healthy controls 9 . The studies indicated that modulation of glutamate and GABA levels could be a novel therapeutic strategy for treatment of early stages of MS 9 .
GABA is a major inhibitory neurotransmitter with antidepressant, antihypertensive, anti-diabetic effects. It regulates pain sensations, anxiety, and serum lipid levels in humans 10 . Apparently, GABA has an immunomodulatory effect and a specific role in autoimmune diseases like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. It is a non-protein amino acid synthesized by glutamic acid decarboxylase (GAD) in the irreversible reaction of α-decarboxylation of L-glutamic acid 11 . The GAD pathway is encoded by the gadB and gadC genes regulated by the GadR activator; it is induced by presence of glutamate and/or environmental stresses such as acidity, osmotic stress, or starvation and has a role in a stress-resistance 12 . GABA is produced by various microorganisms including lactic acid bacteria (LAB) 13, 14 .
In our previous work the probiotic properties of GABA-producing Lactobacillus brevis BGZLS10-17 natural isolate from artisanal cheese from Zlatar Mountain was evaluated 13 . The high adhesion of BGZLS10-17 strain to Caco-2 cells and the exclusion ability of Escherichia coli ATCC25922 and Salmonella O n L i n e F i r s t enterica C29039 was revealed. Interestingly, we have shown in an in vitro model of inflammation-induced disruption of the intestinal barrier that GABA-containing supernatant of BGZLS10-17 culture decreased the production of IL-8 and increased the expression of TGF-β cytokines and had protective effect on the intestinal epithelial barrier through stimulation of expression of tight junction proteins 15 . As the restraint of exacerbated inflammation and the stabilisation of intestinal barrier was suggested to be very important for MS treatment, in this work we investigated the effect of GABA-producing BGZLS10-17 as well as GABAenriched supernatant of this probiotic strain on clinical symptoms of EAE in DA rats. Our aim was to test if BGZLS10-17 could be used as adjunct starter culture for production of GABA-enriched dairy functional food for maintenance of various inflammatory diseases, including multiple sclerosis.
EXPERIMENTAL

Bacterial strains
Lactobacillus brevis BGZLS10-17, GABA-producing natural dairy isolate from artisanal Zlatar cheese (bacterial collection of Laboratory for Molecular Microbiology, IMGGE) was used in this study. BGZLS10-17 was cultured in MRS broth (Merck, Darmstadt, Germany) at 37 °C under anaerobic conditions using Anaerocult A (Merck). In order to stimulate GABA production, the strain was cultivated in MRS broth with addition of 0.6 % monosodium glutamate (MSG -Acros organics, Morris Plains, NJ, United States) for 48 h at 37 °C under anaerobic conditions. Supernatants were neutralised to pH 7 and then filtrated through 0.22 μM filters (Sarstedt, Nümbrecht, Germany). For fermentation purposes strain Streptococcus thermophilus BGKMJ1-36 was used. BGKMJ1-36 was grown in M17 medium (pH 7.2) (Merck) supplemented with 0.5 % (w/v) glucose (GM17) at 37 °C, under anaerobic conditions.
Molecular characterisation of the gad gene
The total DNA of lactobacilli strain was extracted using the QIA DNA Mini Kit (Qiagen GmbH, Hilden, Germany). The PCR amplification of complete gad gene was performed by gadBBF (5'-GACCGGTCATGAGGCG-3') and gadBBR (5'-CATTACTCGCCGTTCGGC-3') primers (this work). Briefly, 25 µl reaction contained 500 ng/µl of DNA, 0.5 U of Q5 High-Fidelity DNA Polymerase (New England BioLabs, Inc.), 200 µM of each deoxynucleoside triphosphate, 0.5 µM of both primers and 1Q5 Reaction Buffer. Conditions for DNA amplification were: denaturation at 98 °C for 30 s; 30 cycles of polymerization at 98 °C for 10 s, 38 °C for 30 s, and 72 °C for 1 min 30 s; and elongation at 72 °C for 5 min. The obtained PCR amplicons were purified (Qiagen, GmbH, Hilden, Germany) and sequenced (Macrogen, Amsterdam, the Netherlands). Sequence annotation and the database searches for sequence similarities were performed with the BLAST tool available online (http://www.ncbi.nlm.nih.gov/ BLAST).
Data base search and in silico phylogenetic analysis
Database search for protein sequence similarities was done using the BLAST tool (http://blast.ncbi.nlm.nih.gov). To build the GAD protein profile the PSI-BLAST 15 homology searches were restricted to Lactobacillaceae and e-value cut-off of 1e-4. All hits that exhibited at least 40 % identity and over 70 % of the query fragment length were maintained for further analysis. GAD protein from L. brevis BGZLS10-17 was used as a GAD prototype.
O n L i n e F i r s t
The phylogenetic interpretations were obtained by MEGA version 7.0 16 . Multiple protein sequence alignments were performed using Clustal W with default parameters. The construction of a GAD phylogenetic tree was conducted by the maximum-likelihood (ML) method using a Jones-Taylor-Thornton (JTT) model. Bootstrapping of 1000 replicates was used to infer confidence levels of ML trees. An online tool (iTOL) v3 was used for the tree display 17 . pH evolution in MRS with and without MSG L. brevis BGZLS10-17 was inoculated (2 %) in MRS medium (Merck) and MRS medium with addition of 1 % MSG (Acros organics) and the pH was measured with Thermo scientific Orion Versa Star Advanced Electrochemistry Meter using Orion™ Versa Star Pro™ Meter Software every 15 min for 48 h. Growth was monitored by measuring the optical density at 600 nm (OD600) (Eppendorf Bio Photometer Plus, Hamburg, Germany) and bacterial cells were counted by plating serial dilutions on MRS agar plates.
Experimental animals, induction of experimental autoimmune encephalomyelitis (EAE), treatment and evaluation
Female DA rats (8-10 weeks of age) were maintained in the animal facility of the Institute for Biological Research "Sinisa Stankovic". Animal experiments were approved by the local ethics committee (Institute for Biological Research "Sinisa Stankovic", No. 03-1/15). Housing of the rats was performed under conventional conditions. Five rats were kept in the same cage. Animals, 5 per group, were separated in four groups: group 1 was treated with 50 ml/day MRS broth -control group; group 2 treated with BGZLS10-17 strain grown for 16 h in MRS.
(colony forming units [CFU]/ml ~ 10 9 ); group 3 treated with 50 ml/day of cell free supernatant obtained from BGZLS10-17 cultivated for 48 h in MRS without MSG (no GABA production); group 4 treated with 50 ml/day of cell free supernatant from BGZLS10-17 cultivated for 48 h in MRS with MSG (stimulation of GABA production). Each treatment lasted 30 days. Differences between the control and experimental groups were compared using Student's t-test. Values of p <0.05 or less were considered statistically significant.
Proteolytic activity
Proteolytic activities of the BGZLS10-17 strain were essentially assayed as described previously 18 . For this purpose, BGZLS10-17 was grown on MCA plates for 48 h, at optimal growth conditions prior to cell collection. Collected fresh cells (10 mg) were resuspended in 50 μl of 0.1 M sodium-phosphate buffer pH 6.8, to approximate density of 10 10 cells/ml. The cell suspension was mixed with substrate dissolved in the same buffer at a 1:1 volume ratio and incubated for 3 h and 24 h at 37 °C. The substrates used for proteolytic assay were either α-, β-, κ-casein fractions or total casein (5 mg/ml) (Sigma, St. Louis, MO, USA). After that, cells were pelleted by centrifugation (5 min at 12.000 g), and the supernatant was then used for preparation of samples for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Fermented milk beverage preparation To produce fermented milk beverage strains L. brevis BGZLS10-17 and Streptococcus thermophilus BGKMJ1-36 were used. BGZLS10-17 was cultivated for 16 h in 100 ml of MRS broth at 37 °C anaerobically while BGKMJ1-36 was grown in 100 ml of GM17 broth for 16 h at 37 °C anaerobically.
The acidification ability of the strain BGZLS10-17 in skim milk was tested in following way: i) 4 % of BGZLS10-17 of 16 h old culture was inoculated in 100 ml of pasteurized milk (Imlek, Belgrade, Serbia) with or without yeast extract (YE) 4 g/l (Torlak, Belgrade, Serbia) or MRS broth 20 % (Merck). Fermentation process was monitored for 24 h; ii) 1 % of BGKMJ1-36 of 16 h old culture was inoculated in 100 ml of pasteurized milk (Imlek) and the fermentation process was monitored for 6 h or until the pH reached 4.9; iii) Mixed culture: 4 % of BGZLS10-17 and 1 % of BGKMJ1-36 were inoculated in 100 ml of pasteurized milk (Imlek) and the fermentation process was monitored for 6 h or until the pH reached 4.9. All fermentation processes were performed at 42 °C. Then the cultures were cooled to 5 °C for 2 h. After this cooling time, the storage time was considered equal to 0 day (d). During storage (at 5 °C) every 7 d cultures were taken to determine pH and viability of bacteria (CFU/ml) until 21 d. All experiments were done in triplicates.
RESULTS AND DISCUSSION
Molecular characterization and phylogenetic analysis of the L. brevis gadB gene L. brevis BGZLS10-17, the high GABA-producing strain 13 was screened for the presence of the gad gene. The PCR amplification with primers complementary to the complete gad genes gave a PCR product of 1440 bp. The predicted amino acid sequences of L. brevis BGZLS10-17 showed 98 % identity to the gadB of L. brevis (WP_011666890.1).
The maximum likelihood (ML) phylogenetic analysis of GAD proteins from the entire Lactobacillacae family separated GAD proteins into three groups (Figure 1) . Group I consists of the GAD proteins from L. aviarius, L. antri, L. oris and L. reuteri. Group II includes BGZLS10-17 isolate (Figure 1 O n L i n e F i r s t Figure 1 . Phylogenetic inferences of GAD protein among Lactobacilaceae. A phylogenetic tree of GAD proteins was constructed with the maximum likelihood (ML) method using a Jones-Taylor-Thornton (JTT) model distance matrix. The confidence levels were computed from 1000 bootstrap resamples of alignment used for phylogenetic inferences by ML method. The gray shades represent the three different groups (I-III) consisting of Lactobacillus spp. from the database and the BGZLS10-17 isolate (black arrow).
Treatment of EAE
In order to evaluate the possible beneficial effect of GABA on autoimmune diseases, in this study we treated DA rats, prone to EAE induction, with the GABA-producing strain BGZLS10-17, as well as with GABA-enriched cell-free supernatant of BGZLS17-10 grown for 48 h. The results of this in vivo study showed that the strain L. brevis BGZLS10-17 was able to decrease the disease severity in DA rats. Treatment with BGZLS10-17 delayed disease manifestation and shortened the duration of the disease, while the peak of the disease was entirely reduced, and the animals were completely recovered after forty days that was not observed in control animals ( Figure 2 ). Figure 2 . The effect of the BGZLS10-17 on the clinical score of EAE in female DA rats. Females DA rats were immunized with SCH mixed with CFA, which led to the manifestation of symptoms similar to multiple sclerosis. The animal control group consumed MRS medium, while the experimental group consumed BGZLS10-17 grown in MRS medium for 16 h (10 9 cells/rat daily). x-axis represents clinical score of EAE symptoms, while y-axis represents days after immunization. Clinical picture of the disease was monitored from 7 up to 42 days.
O n L i n e F i r s t
The results are presented as mean values (n = 5 rats per group) ± standard deviation. * p <0.05, **p<0.01; d -days.
The amelioration of the EAE symptoms also occurred when GABA-enriched cell-free supernatant of the L. brevis BGZLS10-17 grown for 48 h was used, clearly indicating the role of GABA produced by BGZLS10-17 in improvement of EAE prognosis. However, slight improvement of the EAE symptoms was scored when the cell-free supernatant of the BGZLS10-17 grown for 48 h in MRS without MSG was used suggesting that other beneficial metabolites (molecules) in cell-free supernatant of the BGZLS10-17 could act as a possible postbiotic (Figure 3 a and b ). Comparing the effects of live strain and its supernatants, it can be observed that treatment with both live BGZLS10-17 and its GABA-containing supernatant alleviate the development of the second peak of EAE (relapse), while application of the live strain shows more significant effect in alleviating EAE symptoms in this phase of the disease. At the same time only the treatments with supernatants statistically delay the onset of the disease and that could be the result of the time needed for the live strain to colonize the GIT, while bioactive molecules contained in the supernatants can achieve its effect immediately after implementation. 
GABA-mediated pH resistance of BGZLS10-17
Hence, in order to use the strain L. brevis BGZLS10-17 as probiotic for prevention and/or treatment of autoimmune diseases, successful colonization of the host is needed. In that order, orally acquired bacteria must survive the extreme acidic stress in the host stomach. Given that GABA production from glutamate (MSG) is by far the most potent acid resistance system in bacteria 12, 19 our aim was to investigate the pH changes in GABA-producing strain L. brevis BGZLS10-17 culture during 24 h and 48 h of incubation (Figure 4 ). The pH evolution was dependent on cultivation conditions. Monitoring of the pH of BGZLS10-17 culture grown in MRS with and without MSG revealed that after 48 h of incubation significantly higher pH was observed in the BGZLS10-17 culture grown in medium supplemented with MSG ( Figure 4) . These results were consistent with our previous HPLC analysis that showed the high GABA concentration in supernatant of BGZLS10-17 grown in MRS with MSG for 48 h 13 . Although the OD 600 was similar for both BGZLS10-17 cultures grown in MRS and MRS with MSG for 24 and 48 h ( Figure 5a ) the number of viable bacteria was remarkably higher if they were grown in medium with MSG after 48 h (Figure 5b) . Our results obtained for the pH evolution in L. brevis BGZLS10-17 culture confirm that GABA might be involved in the pH regulation.
O n L i n e F i r s t
According to Papadimitriou et al. 12 , the extracellular pH increases during the conversion of glutamate to the more alkaline GABA. The presence of glutamate and/or environmental stress, in this case stationary phase, characterized by depletion of the essential nutrients and acidifaction of the growth medium caused by formation of lactic acid, induced the GAD pathway in the strain L. brevis BGZLS10-17 after the growth in MRS with MSG for 48 h, enabling the pH resistance and higher viability comparing to the strain BGZLS10-17 grown in MRS without MSG. O n L i n e F i r s t Figure 5 . Monitoring of the growth of BGZLS10-17 for 48 h in MRS medium and MRS medium with MSG. Optical density (OD) measured at 600 nm (a) and logarithmic value of CFU ml -1 for BGZLS10-17.
Proteolytic activity
Another important characteristic of probiotic strains used in functional dairy food is their ability to degrade casein, the major milk protein. Lactic acid bacteria are multiple amino acid auxotrophs, hence to grow in milk they depend on the expression of a complex proteolytic system encompasing a cell-wall bound extracellular serine proteinase breaking down casein, oligopeptide transport systems and the intracellular peptidases that hydrolyse oligopeptides to free amino acids 20 . Moreover, during milk fermentation biologically active peptides could be released as a result of proteolytic activity giving the additional healthpromoting feature to the functional dairy food 21, 22 .
Hence, the proteolytic activity of the strain L. brevis BGZLS10-17 was analysed and the results revealed that after 3 h only partial degradation of α -O n L i n e F i r s t caseine was observed ( Figure 6 ), while the complete casein degradation (α -, βand κ -casein) was achieved after 24 h ( Figure 6 ), pointing to the weak proteolytic activity. 
The fermented milk beverage preparation
Additionaly, the fermentation time during the preparation of fermented milk beverage with strain L. brevis BGZLS10-17 was followed. The results of fermentation time of BGZLS10-17 for the prepared fermented milk beverage (pH measurement during 24 h) are prezented in Table I   TABLE I . pH values (means ± SD) of fermented milk beverage manufactured with BGZLS10-17
Name pH
Initial After 3 h After 4 h After 5 h After 6 h After 24 h BGZLA10-17 in milk 6.57±0.01 6.3±0.01 6.3±0.03 6.20±0.01 6.18±0.02 5.39±0.01 BGZLS10-17 in milk with YE 6.58±0.01 6.21±0.03 6.20±0.03 6.20±0.02 6.13±0.02 4.44±0.03 BGZLS10-17 in milk with MRS 6.41±0.02 6.13±0.03 6.10±0.01 6.05±0.01 6.0±0.03 4.28±0.03
The results indicated very slow process of fermentation of milk, as well as milk with YE or milk with MRS, inoculated with BGZLS10-17 after 24 h. Moreover, the rheological properties of the fermented beverage were also unsatisfactory, with lot of lumps, indicating that due to weak proteolytic activity strain BGZLS10-17 has poor technological characteristics. Hence, in order to be used in functional dairy food, the strain L. brevis BGZAL10-17 should be combined with dairy starter culture bacteria. Therefore, in order to prepare fermented beverage with desirable attributes the strain BGZLS10-17 together with the strain S. thermophilus BGKMJ1-36 in pasteurized milk. The fermentation process was monitored and the number of viable bacteria was observed during 7 h. Results are presented in Table II. O n L i n e F i r s t The number of bacteria for both strains was determined at the end of the fermentation process and it was 810 8 for BGZLS10-17 and 5.510 8 for BGKMJ1-36. The results clearly indicated that the mixed culture of BGZLS10-17 and BGKMJ1-36 had much better technological properties and that could be suitable for preparing of fermented milk beverage.
Moreover, fermented beverage prepared by mixed culture containing BGZLS10-17 and BGKMJ1-36 was stored at 5°C and the stability of pH and bacterial viability were monitored each 7 d until 21 d. The results are presented in Table III . The obtained results indicate that the manufactured fermented beverage was stable during 21 days, since the pH and the bacterial viability were not significantly changed over time. CONCLUSION The results obtained in this study highly indicate the positive role of GABAproducing strain BGZLS10-17 in amelioration of the EAE symptoms in DA rats that could be accredited to GABA present in the cell-free supernatant. Besides, technological characterization suggests promising use of the strain L. brevis BGZLS10-17 in combination with the autochthonous strain S. thermophilus BGKMJ1-36 as functional starter culture for production of GABA-enriched fermented beverage under controlled conditions, although the beneficial effects of the strain BGZLS10-17 on autoimmune diseases should be confirmed in clinical trials, according to EFSA regulations 23 Мултипла склероза (МС) је хронично аутоимунско обољење централног нервног система. Циљ овог рада је био изучавање пробиотичког ефекта произвођача γаминобутерне киселине (ГАБА), соја Lactobacillus brevis BGZLS10-17, на Dark Agouti (ДА) пацовима осетљивим на индукцију експерименталног аутоимунског енцефаломијелитиса (ЕАЕ), експерименталног модела МС. Пацовима су свакодневно праћени клинички симптоми ЕАЕ. Резултати студије су показали да орална примена L. brevis BGZLS10-17 ублажава симптоме ЕАЕ код ДА пацова, одложен је почетак болести, скраћено трајање болести, смањен интензитет болести у периоду када су симптоми код контрола најјаче изражени, а занимљиво је и да се животиње након четрдесет дана потпуно опорављају, што код контролних животиња које нису биле третиране пробиотиком L. brevis BGZLS10-17 није био случај. Побољшање ЕАЕ симптома је забележено и након примене супернатанта соја L. brevis BGZLS10-17 гајеног 48 сати у медијуму за раст бактерија са и без додатка прекурсора ГАБА, мононатријум глутамата (МСГ). Добијени резултати указују да би ГАБА коју производи сој L. brevis BGZLS10-17 могла бити одговорна за ублажавање симптома ЕАЕ. Пробиотички ефекат соја L. brevis BGZLS10-17 ће бити даље тестиран у клничким студијама на људима, како би сој могао да се користи као пробиотик у функционалној храни за пацијенте оболеле од аутоимунских болести. 
